| Primary |
| Acromegaly |
60.6% |
| Hypertension |
10.8% |
| Pituitary Tumour |
3.3% |
| Depression |
2.8% |
| Diabetes Mellitus |
2.8% |
| Gigantism |
2.8% |
| Hypopituitarism |
1.9% |
| Hypothyroidism |
1.9% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Hypothalamo-pituitary Disorder |
1.4% |
| Type 2 Diabetes Mellitus |
1.4% |
| Insulin-like Growth Factor Increased |
1.3% |
| Pituitary Tumour Benign |
1.3% |
| Blood Pressure Abnormal |
1.1% |
| Blood Thyroid Stimulating Hormone Decreased |
1.1% |
| Ill-defined Disorder |
0.9% |
| Blood Cholesterol Increased |
0.8% |
| Blood Growth Hormone Increased |
0.8% |
| Lipids Abnormal |
0.8% |
| Blood Corticotrophin Decreased |
0.6% |
|
| Death |
13.7% |
| Pituitary Tumour Benign |
8.1% |
| Weight Increased |
8.1% |
| Drug Ineffective |
6.2% |
| Insulin-like Growth Factor Increased |
5.6% |
| Hepatic Enzyme Increased |
5.0% |
| Pituitary Tumour Recurrent |
5.0% |
| Headache |
4.3% |
| Injection Site Pain |
4.3% |
| Nausea |
4.3% |
| Depression |
3.7% |
| Fatigue |
3.7% |
| Hepatitis |
3.7% |
| Hypersensitivity |
3.7% |
| Lipodystrophy Acquired |
3.7% |
| Rash |
3.7% |
| Vomiting |
3.7% |
| Abdominal Distension |
3.1% |
| Diarrhoea |
3.1% |
| Injection Site Reaction |
3.1% |
|
| Secondary |
| Acromegaly |
55.3% |
| Gigantism |
10.6% |
| Pituitary Tumour |
5.7% |
| Pituitary Tumour Benign |
4.1% |
| Blood Pressure Abnormal |
2.8% |
| Abnormal Behaviour |
2.4% |
| Hypertension |
2.0% |
| Hypothalamo-pituitary Disorder |
2.0% |
| Insulin-like Growth Factor Increased |
2.0% |
| Gastrooesophageal Reflux Disease |
1.6% |
| Osteoporosis Prophylaxis |
1.6% |
| Benign Neoplasm |
1.2% |
| Blood Growth Hormone Abnormal |
1.2% |
| Blood Growth Hormone Increased |
1.2% |
| Hypothyroidism |
1.2% |
| Product Used For Unknown Indication |
1.2% |
| Rickets |
1.2% |
| Adrenal Insufficiency |
0.8% |
| Depression |
0.8% |
| Diabetes Mellitus |
0.8% |
|
| Pituitary Tumour Benign |
11.1% |
| Weight Increased |
8.6% |
| Insulin-like Growth Factor Increased |
7.4% |
| Pulmonary Embolism |
6.2% |
| Thyroid Disorder |
6.2% |
| Fatigue |
4.9% |
| Injection Site Pain |
4.9% |
| Nausea |
4.9% |
| Off Label Use |
4.9% |
| Tremor |
4.9% |
| Abdominal Pain |
3.7% |
| Drug Ineffective |
3.7% |
| General Physical Health Deterioration |
3.7% |
| Headache |
3.7% |
| Inflammation |
3.7% |
| Injection Site Bruising |
3.7% |
| Pituitary Tumour |
3.7% |
| Pituitary Tumour Removal |
3.7% |
| Vitamin D Deficiency |
3.7% |
| Abdominal Distension |
2.5% |
|
| Concomitant |
| Acromegaly |
46.3% |
| Product Used For Unknown Indication |
22.4% |
| Pituitary Tumour |
7.5% |
| Hypertension |
4.5% |
| Pituitary Tumour Benign |
4.5% |
| Hypopituitarism |
3.0% |
| Hypothalamo-pituitary Disorder |
3.0% |
| Carcinoid Syndrome |
1.5% |
| Cushing's Syndrome |
1.5% |
| Depression |
1.5% |
| Oesophagitis |
1.5% |
| Off Label Use |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
|
| Glycosylated Haemoglobin Increased |
11.1% |
| Cerebrovascular Accident |
7.4% |
| Death |
7.4% |
| Diverticulum |
7.4% |
| Injection Site Abscess |
7.4% |
| Nervous System Disorder |
7.4% |
| Blood Glucose Decreased |
3.7% |
| Chemical Peritonitis |
3.7% |
| Disorientation |
3.7% |
| Drug Ineffective |
3.7% |
| Haemangioma Of Liver |
3.7% |
| Hip Fracture |
3.7% |
| Hospitalisation |
3.7% |
| Injection Site Haematoma |
3.7% |
| Lung Neoplasm Malignant |
3.7% |
| Mass |
3.7% |
| Mixed Liver Injury |
3.7% |
| Muscle Twitching |
3.7% |
| Nausea |
3.7% |
| Needle Issue |
3.7% |
|
